Top Markets
#1 Helium Helium +110.72%
#2 MowCat MowCat +83.79%
#3 Seeker Seeker +72.11%
#4 AI XOVIA AI XOVIA +52.42%
#5 UnifAI Network UnifAI Network +33.65%
#6 Pons Pons +30.52%
#7 Tensor Tensor +26.60%
#8 TENDIES TENDIES +25.33%
#9 pipedog pipedog +22.04%
#10 Zylo Ecosystem Zylo Ecosystem +21.96%
Coin of the day
Helium Helium
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Classificação em ações #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Preço da ação
$8.74
Última sincronização: 2026-08-28
Valor de mercado
$699.74M
Variação (1 dia)
-4.85%
Variação (1 ano)
-2.29%
País
US
Negociar BridgeBio Oncology Therapeutics Inc. (BBOT)

Categoria

Healthcare
Lucros da BridgeBio Oncology Therapeutics Inc. (BBOT)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da BridgeBio Oncology Therapeutics Inc., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da BridgeBio Oncology Therapeutics Inc. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH